The hematologic consequences of thrombolytic therapy.
D000818:Animals; D001779:Blood Coagulation Factors / Q000032:analysis; D001780:Blood Coagulation Tests; D001792:Blood Platelets / Q000187:drug effects; D004341:Drug Evaluation; D005337:Fibrin / Q000378:metabolism; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis; D005340:Fibrinogen / Q000378:metabolism; D005341:Fibrinolysin / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D006470:Hemorrhage / Q000139:chemically induced*; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy; D010960:Plasminogen Activators / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D013300:Streptokinase / Q000009:adverse effects / Q000276:immunology / Q000494:pharmacology / Q000627:therapeutic use; D013917:Thrombin / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D013923:Thromboembolism / Q000188:drug therapy
D001779:Blood Coagulation Factors; D005338:Fibrin Fibrinogen Degradation Products; D005343:Fibrinolytic Agents; D005337:Fibrin; D005340:Fibrinogen; D013300:Streptokinase; D010960:Plasminogen Activators; D013917:Thrombin; D005341:Fibrinolysin